People  |   Processes   |   Predictions

 LIVE ONLINE 7 October 2021

Advanced Therapies Integrates 2021 Agenda

7th OCTOBER 2021

ALL SESSIONS WILL BE PRESENTED AS PANEL DISCUSSIONS

PLEASE NOTE: Timings may be subject to change.

SESSIONS ARE DIVIDED INTO 3 TRACKS.

DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.

Opening

08:45-09:00

Welcome and Opening Remarks

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Fireside Chat

09:05-09:25

An interview with…

TRENDING TECHNOLOGY

NOVEL NETWORKS & FINANCE

PRODUCE AND USE

Session 1

09:35- 10:25

Navigating the regulatory maze

Cell and gene therapies raise specific challenges to securing regulatory approvals. This session will look in detail at those challenges and provide insight into effective regulatory strategies. 

Finding the Funds

Are the existing approaches to financing ATMP developers fit for purpose; what should analysts really be looking for in an Advanced Therapy?

Making Waves: Technologies and development improvements

How good are we at making Advanced Therapies today, what should the future look like?

Session 2

10:35-11:25

Britain’s talent for technology

Does the UK have the right skills and capabilities in place to identify and develop the next generation of ATMPs?

Advanced Relays

Evolving the relationship between developers, regulators, payers, providers and patients to speed ATMP development through to adoption.

Supply Pain

As more ATMPs progress towards the market, there are significant emergent challenges to the supply chain.

Break

11:30 – 11:50

NETWORKING

 

Session 3

11:55-12:45

Getting to Market

A Discussion on Challenges, Opportunities and Market Access within Advanced Therapies; how do we create a robust market economy for Advanced therapies, taking into account costs of goods, manufacture and procurement. Do we need a new business model?

Market forces or forcing the market

What are the current challenges and future opportunities for opening up the ATMP markets?

Productive People

As manufacturing technologies continues to emerge, we must have the skills to deliver the science at scale. How can we ensure that talent tracks with emergent manufacturing trends?

Session 4

12:55-13:45

Solid Support

Solid Tumours present unique challenges for effective treatment, how can cell therapies overcome this?

Go with the (cash) flow

Investments and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?

Due process: GMP translation and manufacture

Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs. 

Break

13:50-14:20

NETWORKING

 

Session 5

14:25-15:15

Fast Forward

What are the emerging therapeutic technologies and what will the next generation of ATMPs look like? Do we have the right capabilities and assets to manufacture them?

Skills: the global gold rush

How can stakeholders come together to address cell and gene therapy’s global talent gap?

Negotiate or collaborate?

In an ever-changing pharmaceutical landscape, successfully bringing a concept to market — and to patients — involves many different stakeholders. How do industry leaders navigate this journey most effectively?

Closing

15:20-15:30

Closing remarks

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Welcome and Opening Remarks

08:45-09:00

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Fireside Chat

09:05-09:25

An interview with….

TRENDING TECHNOLOGY

Session 1:

09:35- 10:25

Let’s get clinical

  • Evaluation and Development for ATMPs is different from the ‘norm’; do we need to rethinking the design of clinical trials for a clear path to commercialisation.
  • Taking learnings from Covid-19 (vaccines), i.e., efficiency in a crisis – what can we learn?

Session 2:

10:35-11:25

Britain’s talent for technology

Does the UK have the right skills and capabilities in place to identify and develop the next generation of ATMPs?

NETWORKING

11:30-11:50

 

Session 3:

11:55-12:45

Precision Thinking

How to expand the development and use of Autologus ATMPs.

Session 4:

12:55-13:45

Solid Support

Solid Tumours present unique challenges for effective treatment, how can cell therapies overcome this?

NETWORKING

13:50-14:20

 

Session 5:

14:25-15:15

Fast Forward

What are the emerging therapeutic technologies and what will the next generation of ATMPs look like?
Do we have the right capabilities and assets to manufacture them?

Closing Remarks

15:20-15:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Welcome and Opening Remarks

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Fireside Chat

09:05-09:25

An interview with….

NOVEL NETWORKS & FINANCE

Session 1:

09:35- 10:25

Finding the Funds

Are the existing approaches to financing ATMP developers fit for purpose; what should analysts really be looking for in an Advanced Therapy?

Session 2:

10:35-11:25

Advanced Relays

Evolving the relationship between developers, regulators, payers, providers and patients to speed ATMP development through to adoption. How healthy are the Technology Assessments for ATMPs, are they revealing the full value?

NETWORKING

11:30-11:50

 

Session 3:

11:55-12:45

Export Strength

What are the current challenges and future opportunities for opening up the ATMP markets?
MHRA, NICE and NHS England are working together can make the UK attractive, but there are lower number of patients in UK as opposed to Europe. So how attractive is the UK for investment? How can investors get quicker and better returns?
Divergence from MHRA and EMA

Session 4:

12:55-13:45

Go with the (cash) flow

Investments and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?

NETWORKING

13:50-14:20

 

Session 5:

14:25-15:15

Skills: the global gold rush

How can stakeholders come together to address cell and gene therapy’s global talent gap?

Closing Remarks

15:20-15:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Welcome and Opening Remarks

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Fireside Chat

09:05-09:25

An interview with….

PRODUCE AND USE

Session 1:

09:35- 10:25

Making Waves: Technologies and development improvements

How good are we at making Advanced Therapies today, what should the future look like?
Focusing on manufacturing technologies and analytical methods and the role of High throughput and automation.

Session 2:

10:35-11:25

Supply Pain

As more ATMPs progress towards the market, there are significant emergent challenges to the supply chain.
What needs to happen to ensure therapies are effectively and efficiently produced?

NETWORKING

11:30-11:50

 

Session 3:

11:55-12:45

Productive People

As manufacturing technologies continues to emerge, we must have the skills to deliver the science at scale. How can we ensure that talent tracks with emergent manufacturing trends?

Session 4:

12:55-13:45

Due process: GMP translation and manufacture

Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs. Can we share knowledge for the greater good of patients and the planet?

NETWORKING

13:50-14:20

 

Session 5:

14:25-15:15

Negotiate or collaborate?

In an ever-changing pharmaceutical landscape, successfully bringing a concept to market — and to patients — involves many different stakeholders. How do industry leaders navigate this journey most effectively?

Closing Remarks

15:20-15:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.

People  |   Processes   |   Predictions

 LIVE ONLINE 7 October 2021